Malha Sahmi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Malha Sahmi has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Anne Marinier
Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, QC, Canada
1 shared publication - Bing Wang
Cryo-Electron Microscopy Core Facility, New York University School of Medicine, New York, NY 10016, USA
1 shared publication - Chang Hwa Jo
Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, Canada
1 shared publication - David C. Schriemer
Department of Biochemistry and Molecular Biology, University of Calgary, Calgary, Canada
1 shared publication - Doris Alexandra Schuetz
Institute for Research in Immunology and Cancer, Laboratory of Intracellular Signaling, Université de Montréal, Montreal, QC, Canada
1 shared publication - Driss Lajoie
Institute for Research in Immunology and Cancer, Laboratory of Intracellular Signaling, Université de Montréal, Montreal, QC, Canada
1 shared publication
Latest Publications
- 29 May 2025
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 388 (6750) , eadp2742
BRAF oncogenic mutants evade autoinhibition through a common mechanism
Uncontrolled activation of the rat sarcoma (RAS)–extracellular signal–regulated kinase (ERK) pathway drives tumor growth, often because of oncogenic BRAF mutations. BRAF regulation, involving monomeric autoinhibition and activation by dimerization, has been intensely scrutinized, but mechanisms enabling oncogenic mutants to evade regulation remain unclear. By using cryo–electron microscopy, we solved the three-dimensional structures of the three oncogenic BRAF mutant classes, including the common V600E variant. These mutations disrupted wild-type BRAF's autoinhibited state, mediated by interactions between the cysteine-rich domain and kinase domain, thereby shifting the kinase domain into a preactivated conformation. This structural change likely results from helix αC displacement. PLX8394, a BRAF inhibitor that stabilizes helix αC in an inactive conformation, restored the autoinhibited conformation of oncogenic BRAF, explaining the properties of this class of compounds.
- 29 May 2025
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 388 (6750) , eadp2742
BRAF oncogenic mutants evade autoinhibition through a common mechanism
Uncontrolled activation of the rat sarcoma (RAS)–extracellular signal–regulated kinase (ERK) pathway drives tumor growth, often because of oncogenic BRAF mutations. BRAF regulation, involving monomeric autoinhibition and activation by dimerization, has been intensely scrutinized, but mechanisms enabling oncogenic mutants to evade regulation remain unclear. By using cryo–electron microscopy, we solved the three-dimensional structures of the three oncogenic BRAF mutant classes, including the common V600E variant. These mutations disrupted wild-type BRAF's autoinhibited state, mediated by interactions between the cysteine-rich domain and kinase domain, thereby shifting the kinase domain into a preactivated conformation. This structural change likely results from helix αC displacement. PLX8394, a BRAF inhibitor that stabilizes helix αC in an inactive conformation, restored the autoinhibited conformation of oncogenic BRAF, explaining the properties of this class of compounds.